Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2008 May 27;70(22 Pt 2):2130-6.
doi: 10.1212/01.wnl.0000289511.20864.2a. Epub 2007 Nov 28.

Lamotrigine in pregnancy: clearance, therapeutic drug monitoring, and seizure frequency

P B Pennell  1 , L Peng, D J Newport, J C Ritchie, A Koganti, D K Holley, M Newman, Z N Stowe
Affiliations
Comparative Study

Lamotrigine in pregnancy: clearance, therapeutic drug monitoring, and seizure frequency

P B Pennell et al. Neurology. .

Abstract

Objective: To characterize the magnitude and course of alterations in total and free lamotrigine (LTG) clearance (Cl) during pregnancy and the postpartum period, to assess the impact of therapeutic drug monitoring (TDM) on seizure frequency, to determine the ratio to individual target LTG concentration that is associated with increased seizure risk, and to evaluate maternal postpartum toxicity.

Methods: A cohort of women were enrolled before conception or during pregnancy in this prospective, observational study. Visits occurred every 1 to 3 months with review of seizure and medication diaries, examination, and blood sampling. Total and free LTG Cls were calculated. Individualized target concentrations were used for TDM. The ratio to target concentration (RTC) was compared between patients with and without increased seizures. A receiver operating characteristic curve determined the threshold RTC that best predicts increased seizure frequency.

Results: Analysis of 305 samples in 53 pregnancies demonstrated increased total and free LTG Cl in all trimesters above nonpregnant baseline (p < 0.001), with peak increases of 94% and 89% in the third trimester. Free LTG Cl was higher in white compared with black women (p < 0.05). Increased seizure frequency (n = 36 women with epilepsy) in the second trimester was associated with a lower RTC (p < 0.001), and RTC < 0.65 was a significant predictor of seizure worsening. An empiric postpartum taper reduced the likelihood of maternal LTG toxicity (p < 0.05) (n = 27). Newborn outcomes were similar to the general population (n = 52).

Conclusions: These novel data contribute to a rational treatment plan and dosing paradigm for lamotrigine use during pregnancy, parturition, and the postpartum period.

PubMed Disclaimer

Conflict of interest statement

Disclosure: Dr. Page B. Pennell has participated in the speaker’s bureau and advisory boards for GlaxoSmithKline and UCB Pharma. She has received research support from GlaxoSmithKline, UCB Pharma, Marinus Pharmaceuticals, and the National Institutes of Health. Dr. D. Jeffrey Newport has received honoraria support from GlaxoSmithKline, Eli Lilly, Pfizer, and AstraZeneca and has received research support from the National Institutes of Health, Eli Lilly, GlaxoSmithKline, and Wyeth. Dr. James C. Ritchie has received research grant support from the National Institutes of Health, the Georgia Cancer Coalition, and the American Foundation for Suicide Prevention. Dr. Archana Koganti has participated in the speaker’s bureaus for Cyberonics and UCB Pharma and has received research support from the National Institutes of Health. Ms. Holley has received salary support for conducting research studies from the National Institutes of Health. Ms. Newman has received salary support for conducting research studies from GlaxoSmithKline, UCB Pharma, Marinus Pharmaceuticals, and the National Institutes of Health. Dr. Zachary N. Stowe has participated in the speaker’s bureaus for GlaxoSmithKline, Pfizer, and Wyeth; serves on the advisory boards for GlaxoSmithKline and Bristol Myers Squibb; and has received research grant support from Pfizer, GlaxoSmithKline, Wyeth, and the National Institutes of Health. Dr. Limin Peng has no conflicts of interest.

Figures

Figure 1
Figure 1
Flow diagram of women enrolled in the study and information used for data analysis AED = antiepileptic drug; GTCSz = generalized tonic– clonic seizure; LTG = lamotrigine; TDM = therapeutic drug monitoring.
Figure 2
Figure 2
Total and free lamotrigine clearance during pregnancy Mean (± SE) total lamotrigine clearance (LTG daily dose [mg/kg]/LTG concentration [mg/L]) and mean (± SE) free lamotrigine clearance (LTG daily dose [mg/kg]/unbound LTG concentration [mg/L]) during nonpregnant baseline and each trimester of pregnancy. * p < 0.001 compared with nonpregnant baseline. δ p < 0.03 compared with first trimester. Cl = clearance.
Figure 3
Figure 3
Lamotrigine clearance and seizures during pregnancy and postpartum Mean (±SE) free lamotrigine clearance (LTG daily dose [mg/kg]/LTG concentration [mg/L]) and percentage of patients who had an increase in seizure frequency compared with preconception baseline, by month gestational age and month postpartum. Cl = clearance.
See this image and copyright information in PMC

References

    1. Karcescki S, Morrell M, Carpenter D. The expert consensus guideline series: treatment of epilepsy. Epil Behav. 2005;2001:A1–A50.
    1. Sabers A, Dam M, Rogvi-Hansen B, et al. Epilepsy and pregnancy: lamotrigine as main drug used. Acta Neurol Scand. 2004;109:9–13. - PubMed
    1. Yonkers KA, Wisner KL, Stowe Z, et al. Management of bipolar disorder during pregnancy and the postpartum period. Am J Psychiatry. 2004;161:608–620. - PubMed
    1. Cunnington M, Ferber S, Quartey G International Lamotrigine Pregnancy Registry Scientific Advisory Committee. Effect of dose on the frequency of major birth defects following fetal exposure to lamotrigine monotherapy in an international observational study. Epilepsia. 2007;48:1207–1210. - PubMed
    1. Holmes LB, Wyszynski DF, Baldwin EJ, Habecker E, Glassman LH, Smith CR. Increased risk for non-syndromic cleft palate among infants exposed to lamotrigine during pregnancy. Birth Defects Res Part A Clin Mol Teratol. 2006;76:5. Abstract.

Publication types